Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
salvia miltiorrhiza + pueraria lobata
- Development stage
- Phase 2
- Lead developer
- The Chinese University of Hong Kong
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A herbal combination therapy consisting of extracts from *Salvia miltiorrhiza* (Danshen) and *Pueraria lobata* (Gegen), developed by the Department of Medicine & Therapeutics at The Chinese University of Hong Kong. This formula is primarily investigated for its cardioprotective and vasoprotective properties, particularly in the treatment of peripheral arterial disease and intermittent claudication. The mechanism of action involves the activation of endothelial nitric oxide synthase (eNOS) to promote vasodilation, alongside anti-inflammatory and anti-oxidative effects mediated through the inhibition of NF-kappaB and TNF-alpha signaling. Clinical studies have demonstrated its potential to improve endothelial function and blood flow in patients with atherosclerotic vascular diseases.
- Other names
- Danshen-Gegen formulaDanshen-Gegen decoction
02
Targets
NF-κBTNFA (Tumor necrosis factor alpha (soluble))MMP9 (Matrix metalloproteinase-9)NOS3 (eNOS)
Beyond the preview
Go deeper on salvia miltiorrhiza + pueraria lobata.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on salvia miltiorrhiza + pueraria lobata.